TY - JOUR
T1 - Human autoimmunity at single cell resolution in aplastic anemia before and after effective immunotherapy
AU - Wu, Zhijie
AU - Gao, Shouguo
AU - Feng, Xingmin
AU - Li, Haoran
AU - Sompairac, Nicolas
AU - Jamshidi, Shirin
AU - Choy, Desmond
AU - Reis, Rita Antunes Dos
AU - Gao, Qingyan
AU - Kajigaya, Sachiko
AU - Alemu, Lemlem
AU - Raffo, Diego Quinones
AU - Groarke, Emma M
AU - Kordasti, Shahram
AU - Patel, Bhavisha A
AU - Young, Neal S
N1 - Publisher Copyright:
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025.
PY - 2025/5/30
Y1 - 2025/5/30
N2 - Severe immune aplastic anemia is a fatal disease due to the destruction of marrow hematopoietic cells by cytotoxic lymphocytes, serving as a paradigm for marrow failure syndromes and autoimmune diseases. To better understand its pathophysiology, we apply advanced single cell methodologies, including mass cytometry, single-cell RNA, and TCR/BCR sequencing, to patient samples from a clinical trial of immunosuppression and growth factor stimulation. We observe opposing changes in the abundance of myeloid cells and T cells, with T cell clonal expansion dominated by effector memory cells. Therapy reduces and suppresses cytotoxic T cells, but new T cell clones emerge hindering robust hematopoietic recovery. Enhanced cell-cell interactions including between hematopoietic cells and immune cells, in particular evolving IFNG and IFNGR, are noted in patients and are suppressed post-therapy. Hematologic recovery occurs with increases in the progenitor rather than stem cells. Genetic predispositions linked to immune activation genes enhances cytotoxic T cell activity and crosstalk with target cells.
AB - Severe immune aplastic anemia is a fatal disease due to the destruction of marrow hematopoietic cells by cytotoxic lymphocytes, serving as a paradigm for marrow failure syndromes and autoimmune diseases. To better understand its pathophysiology, we apply advanced single cell methodologies, including mass cytometry, single-cell RNA, and TCR/BCR sequencing, to patient samples from a clinical trial of immunosuppression and growth factor stimulation. We observe opposing changes in the abundance of myeloid cells and T cells, with T cell clonal expansion dominated by effector memory cells. Therapy reduces and suppresses cytotoxic T cells, but new T cell clones emerge hindering robust hematopoietic recovery. Enhanced cell-cell interactions including between hematopoietic cells and immune cells, in particular evolving IFNG and IFNGR, are noted in patients and are suppressed post-therapy. Hematologic recovery occurs with increases in the progenitor rather than stem cells. Genetic predispositions linked to immune activation genes enhances cytotoxic T cell activity and crosstalk with target cells.
KW - Humans
KW - Anemia, Aplastic/immunology
KW - Autoimmunity/immunology
KW - Single-Cell Analysis/methods
KW - Immunotherapy/methods
KW - T-Lymphocytes, Cytotoxic/immunology
KW - Female
KW - Myeloid Cells/immunology
KW - Male
KW - Interferon-gamma/immunology
KW - Adult
KW - Hematopoietic Stem Cells/immunology
UR - http://www.scopus.com/inward/record.url?scp=105006903413&partnerID=8YFLogxK
U2 - 10.1038/s41467-025-60213-6
DO - 10.1038/s41467-025-60213-6
M3 - Article
C2 - 40447607
SN - 2041-1723
VL - 16
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5048
ER -